重要事件
血液检验
黄金时段
疾病
考试(生物学)
医学
阿尔茨海默病
重症监护医学
心理学
病理
计算机科学
内科学
生物
考古
古生物学
历史
电信
作者
Douglas Galasko,Joshua D. Grill,Jennifer H. Lingler,Judith L. Heidebrink
摘要
A blood test for Alzheimer's disease is now available for clinical use in persons with cognitive impairment. This is an extraordinary milestone, though the amyloid-based PrecivityAD™ test is not without limitations. Pre and post-test counseling are essential. Phosphorylated tau blood tests are likely to follow soon. When used in conjunction with an appropriate clinical evaluation, blood tests provide the opportunity for an early, accurate, and accessible diagnosis of Alzheimer's disease. Standalone use, however, carries a significant risk of misinterpretation and is strongly discouraged. Now is the time to develop appropriate use criteria to guide the use of these promising assays.
科研通智能强力驱动
Strongly Powered by AbleSci AI